To examine the role of systemic activation of the complement system (assessed by levels of circulating C3a, Ba, and sC5b-9) in patients (n = 122) with advanced age-related macular degeneration, geographic atrophy, and neovascular age-related macular degeneration, compared with cataract controls (n = 27).
Methods:
Plasma complement factors were measured using enzyme-linked immunosorbent assays. Statistical analysis included univariate and multivariate logistic regression (p < 0.05).
Results:
Adjusted for age, the odds ratios of C3a and sC5b-9 for any advanced age-related macular degeneration were 1.78 (95% confidence interval = 1.16–2.73, p < 0.01) and 1.20 (95% confidence interval = 1.04–1.39, p = 0.01), respectively. We found a significantly elevated adjusted odds ratio of C3a (adjusted odds ratio = 1.71, 95% confidence interval = 1.12–2.60, p = 0.01) and sC5b-9 (adjusted odds ratio = 1.22, 95% confidence interval = 1.04–1.43, p = 0.01) for neovascular age-related macular degeneration. Adjusted for age, neither C3a, sC5b-9, nor Ba were associated with geographic atrophy.
Conclusion:
We suggest a role for elevated plasma levels of C3a and sC5b-9 in patients with neovascular age-related macular degeneration. The study’s results reinforce the need for more investigation to assess the impact of therapeutic interventions targeted at the complement signaling pathways in age-related macular degeneration.
FerrisFLIIIWilkinsonCPBirdA, et al. Clinical classification of age-related macular degeneration. Ophthalmology2013; 120: 844–851.
4.
CrabbJW. The proteomics of drusen. Cold Spring Harb Perspect Med2014; 4(7): a017194.
5.
AndersonDHMullinsRFHagemanGS, et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol2002; 134(3): 411–431.
6.
MullinsRFRussellSRAndersonDH, et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J2000; 14(7): 835–846.
7.
LambertNGElShelmaniHSinghMK, et al. Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res2016; 54: 64–102.
8.
AmbatiJAmbatiBKYooSH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol2003; 48(3): 257–293.
9.
HolzFGStraussECSchmitz-ValckenbergS, et al. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology2014; 121: 1079–1081.
10.
KhandhadiaSCiprianiVYatesJR, et al. Age-related macular degeneration and the complement system. Immunobiology2012; 217: 127–146.
11.
WeberBHCharbel IssaPPaulyD, et al. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int2014; 111: 133–138.
12.
WhitmoreSSSohnEHChircoKR, et al. Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy. Prog Retin Eye Res2015; 45: 1–29.
13.
FritscheLGFarissRNStambolianD, et al. Age-related macular degeneration: genetics and biology coming together. Annu Rev Genomics Hum Genet2014; 15: 151–171.
14.
EdwardsAORitterRIIIAbelKJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science2005; 308: 421–424.
15.
HagemanGSAndersonDHJohnsonLV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A2005; 102(20): 7227–7232.
16.
HainesJLHauserMASchmidtS, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science2005; 308: 419–421.
17.
AndersonDHRadekeMJGalloNB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res2010; 29(2): 95–112.
18.
WangLClarkMECrossmanDK, et al. Abundant lipid and protein components of drusen. PLoS ONE2010; 5(4): e10329.
19.
NozakiMRaislerBJSakuraiE, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A2006; 103(7): 2328–2333.
20.
SchickTSteinhauerMAslanidisA, et al. Local complement activation in aqueous humor in patients with age-related macular degeneration. Eye (Lond)2017; 31(5): 810–813.
21.
ReynoldsRHartnettMEAtkinsonJP, et al. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci2009; 50(12): 5818–5827.
22.
LechnerJChenMHoggRE, et al. Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: complement activation in AMD. Immun Ageing2016; 13: 4.
23.
SivaprasadSAdewoyinTBaileyTA, et al. Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol2007; 125(4): 515–519.
24.
SchollHPCharbel IssaPWalierM, et al. Systemic complement activation in age-related macular degeneration. PLoS ONE2008; 3: e2593.
25.
MachalinskaADziedziejkoVMozolewska-PiotrowskaK, et al. Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res2009; 42(1): 54–59.
26.
Lores-MottaLPaunCCCorominasJ, et al. Genome-wide association study reveals variants in CFH and CFHR4 associated with systemic complement activation: implications in age-related macular degeneration. Ophthalmology2018; 125: 1064–1074.
27.
RistauTPaunCErsoyL, et al. Impact of the common genetic associations of age-related macular degeneration upon systemic complement component C3d levels. PLoS ONE2014; 9(3): e93459.
28.
SmailhodzicDKlaverCCKleveringBJ, et al. Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. Ophthalmology2012; 119(2): 339–346.
29.
HolersVM. Complement and its receptors: new insights into human disease. Annu Rev Immunol2014; 32: 433–459.
30.
Muller-EberhardHJ. Molecular organization and function of the complement system. Annu Rev Biochem1988; 57: 321–347.
31.
FalkRJPodackEDalmassoAP, et al. Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. Am J Pathol1987; 127(1): 182–190.
LynchAMPatnaikJLCathcartJN, et al. Colorado age-related macular degeneration registry: design and clinical risk factors of the cohort. Retina2019; 39: 656–663.
34.
MorganBP. The membrane attack complex as an inflammatory trigger. Immunobiology2016; 221(6): 747–751.
35.
HaddersMABubeckDRoversiP, et al. Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep2012; 1(3): 200–207.
36.
RusVMalideDBolosiuHD, et al. Levels of SC5b-9 complement complex in plasma and synovial fluid of patients with rheumatic disease. Med Interne1990; 28(4): 305–310.
37.
HertleEvan GreevenbroekMMArtsIC, et al. Complement activation products C5a and sC5b-9 are associated with low-grade inflammation and endothelial dysfunction, but not with atherosclerosis in a cross-sectional analysis: the CODAM study. Int J Cardiol2014; 174: 400–403.
38.
KleinRJZeissCChewEY, et al. Complement factor H polymorphism in age-related macular degeneration. Science2005; 308: 385–389.
39.
ChircoKRTuckerBAStoneEM, et al. Selective accumulation of the complement membrane attack complex in aging choriocapillaris. Exp Eye Res2016; 146: 393–397.
40.
BoraPSSohnJHCruzJM, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol2005; 174(1): 491–497.
41.
MyersCEKleinBEGangnonR, et al. Cigarette smoking and the natural history of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology2014; 121(10): 1949–1955.
42.
WoodellARohrerB. A mechanistic review of cigarette smoke and age-related macular degeneration. Adv Exp Med Biol2014; 801: 301–307.
43.
KunchithapauthamKAtkinsonCRohrerB. Smoke exposure causes endoplasmic reticulum stress and lipid accumulation in retinal pigment epithelium through oxidative stress and complement activation. J Biol Chem2014; 289(21): 14534–14546.
44.
SeddonJMCoteJDavisN, et al. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch Ophthalmol2003; 121(6): 785–792.
45.
LynchAMMurphyJRGibbsRS, et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG2010; 117(4): 456–462.
46.
LynchAMEckelRHMurphyJR, et al. Prepregnancy obesity and complement system activation in early pregnancy and the subsequent development of preeclampsia. Am J Obstet Gynecol2012; 206(5): 428.e1–428.e8.
MicklischSLinYJacobS, et al. Age-related macular degeneration associated polymorphism rs10490924 in ARMS2 results in deficiency of a complement activator. J Neuroinflammation2017; 14(1): 4.
49.
MollnesTEGarredPBergsethG. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol1988; 73(3): 484–488.
50.
EvansJRLawrensonJG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev2012; 1: CD000253.
